Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What are Viruses?00:50

What are Viruses?

128.3K
Overview
128.3K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

6.1K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

248
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
248
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

596
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
596
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

311
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
311

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update.

Hepatology international·2026
Same author

Detection and characterization of Hepatitis B virus double-stranded linear DNA-derived covalently closed circular DNA in chronic hepatitis B patients.

PLoS pathogens·2026
Same author

Nonadherence to Antiviral Therapy Leading to Severe Hepatic Decompensation in a Patient With Chronic Hepatitis B.

ACG case reports journal·2026
Same author

Development of an NGS-Based Estimation of Integrated HBV DNA in Liver Biopsies and Detection in Liquid Biopsies.

Journal of medical virology·2025
Same author

Integrated DNA estimation in tissue biopsy and detection in liquid biopsy by HBV-targeted NGS assay.

medRxiv : the preprint server for health sciences·2024
Same author

Availability of point-of-care HBV tests in resource-limited settings.

The lancet. Gastroenterology & hepatology·2024

Related Experiment Video

Updated: Feb 9, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Hepatitis B virus infection.

Man-Fung Yuen1,2, Ding-Shinn Chen3,4, Geoffrey M Dusheiko5

  • 1Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.

Nature Reviews. Disease Primers
|June 8, 2018
PubMed
Summary
This summary is machine-generated.

Chronic Hepatitis B virus (HBV) infection affects 3.5% globally. Current therapies suppress HBV replication, but new treatments aim for functional cure, reducing long-term complications like cirrhosis.

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.1K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Related Experiment Videos

Last Updated: Feb 9, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.1K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis B virus (HBV) establishes persistent infections via immune anergy, affecting 3.5% of the global population.
  • Chronic HBV infection progresses through distinct clinical phases, often lasting decades.
  • Diagnosis relies on serum markers and liver biopsies for assessing disease severity and guiding treatment.

Purpose of the Study:

  • To provide a comprehensive overview of Hepatitis B virus infection.
  • To discuss epidemiology, immune pathophysiology, diagnosis, prevention, and management strategies.
  • To highlight the pursuit of functional cure for chronic HBV infection.

Main Methods:

  • Review of epidemiological data on HBV prevalence and incidence.
  • Analysis of immune mechanisms underlying chronic HBV infection and immune anergy.
  • Evaluation of current diagnostic markers and therapeutic approaches, including antiviral agents and immunomodulators.

Main Results:

  • Vaccination and antiviral therapies are reducing HBV incidence and viral load.
  • Antiviral agents suppress HBV replication but necessitate long-term treatment.
  • Novel compounds are under investigation to achieve HBV surface antigen seroclearance (functional cure).

Conclusions:

  • Functional cure of chronic HBV infection is associated with higher remission rates and reduced risk of cirrhosis and hepatocellular carcinoma.
  • Continued research into novel therapeutics is crucial for achieving sustained remission and preventing severe liver disease.
  • A multi-faceted approach encompassing prevention, diagnosis, and advanced management is essential for controlling the HBV burden.